Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management …
K Dimopoulos, G Giannakoulas, SJ Wort… - Current opinion in …, 2008 - journals.lww.com
K Dimopoulos, G Giannakoulas, SJ Wort, MA Gatzoulis
Current opinion in cardiology, 2008•journals.lww.comAlthough new advanced therapies hold promise in PAH secondary to CHD, long-term data
are clearly needed. Advanced therapies should be considered when other causes of
functional limitation, such as iron deficiency, have been first addressed. Expertise in CHD as
well as PAH is essential for providing adequate care for this patient group with a unique
pathophysiology.
are clearly needed. Advanced therapies should be considered when other causes of
functional limitation, such as iron deficiency, have been first addressed. Expertise in CHD as
well as PAH is essential for providing adequate care for this patient group with a unique
pathophysiology.
Summary
Although new advanced therapies hold promise in PAH secondary to CHD, long-term data are clearly needed. Advanced therapies should be considered when other causes of functional limitation, such as iron deficiency, have been first addressed. Expertise in CHD as well as PAH is essential for providing adequate care for this patient group with a unique pathophysiology.
Lippincott Williams & Wilkins以上显示的是最相近的搜索结果。 查看全部搜索结果